At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 261 enrolled
Drug / intervention
Escitalopramdrug
Likely dose
Escitalopram 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Improving Quality of Life and Social Functionality With Escitalopram in the Treatment of Major Depressive Disorder With Anxiety Symptom
In Brief
A Phase 4 clinical trial evaluating Escitalopram for Depressive Disorder, Major. Completed, enrolled 261 participants across 10 sites.
Detailed Summary
The purpose of this study is to evaluate the impact of escitalopram on quality of life and social functionality in patients with major depressive disorder with anxiety symptom.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Major
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 2013
Enrollment StartMar 2014
Primary CompletionMay 2015
TodayJul 2026
First PostedJun 6, 2013
Enrollment StartMar 1, 2014
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 13.1 years ago
Interventions
Escitalopramdrug
Escitalopram will be administered as oral tablets 10 mg per day and then the dose of escitalopram will be flexibly adjusted up to maximum of 20 mg per day for the next 7 weeks, based on the investigator's clinical judgment.